Hsbc Holdings PLC decreased its position in Kodiak Sciences Inc. (NASDAQ:KOD – Get Rating) by 13.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,501 shares of the company’s stock after selling 4,211 shares during the quarter. Hsbc Holdings PLC owned 0.05% of Kodiak Sciences worth $208,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. grew its holdings in shares of Kodiak Sciences by 20.5% in the 1st quarter. BlackRock Inc. now owns 3,435,960 shares of the company’s stock valued at $26,526,000 after acquiring an additional 584,762 shares in the last quarter. Point72 Asset Management L.P. bought a new position in Kodiak Sciences during the second quarter worth about $4,136,000. Krensavage Asset Management LLC bought a new position in Kodiak Sciences during the first quarter worth about $3,479,000. Walleye Capital LLC grew its holdings in Kodiak Sciences by 1,904.5% during the first quarter. Walleye Capital LLC now owns 356,093 shares of the company’s stock worth $2,749,000 after purchasing an additional 338,328 shares during the period. Finally, ExodusPoint Capital Management LP grew its holdings in Kodiak Sciences by 1,333.7% during the third quarter. ExodusPoint Capital Management LP now owns 271,411 shares of the company’s stock worth $2,101,000 after purchasing an additional 252,480 shares during the period. Institutional investors and hedge funds own 80.02% of the company’s stock.
Kodiak Sciences Stock Down 5.7 %
Shares of KOD stock opened at $5.65 on Friday. The firm has a 50 day moving average price of $7.52 and a two-hundred day moving average price of $7.76. The company has a market capitalization of $295.55 million, a PE ratio of -0.83 and a beta of 1.79. Kodiak Sciences Inc. has a 12-month low of $4.90 and a 12-month high of $12.80.
Analysts Set New Price Targets
Kodiak Sciences Profile
Kodiak Sciences, Inc is a clinical-stage biopharmaceutical company. The firm engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD.
- Get a free copy of the StockNews.com research report on Kodiak Sciences (KOD)
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
- Oracle Has Spoken: Shares Fall 5%
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.